Suvoda Launches New Drug Optimization as Part of Latest Interactive Response Technology Release
Added feature offers cost savings and the ability to reduce carbon footprint, company says.
Suvoda LLC, a clinical trial technology company, announced a new advanced drug optimization feature as part of its latest interactive response technology (IRT) release. According to the company, this feature offers sponsors of clinical drug trials improved drug supply management, delivering cost savings, and helping companies to reduce their carbon footprint. In the past, supply strategies depended on static quantities of initial drug shipments and buffers, often leading to excessive orders to ensure enough medication is available during a trial.
"Suvoda's new enhancement is an example of how we listen to the needs of our customers and deliver tools that help our sponsors and partners," said Lisa Li, director of IRT product management, Suvoda. "We heard from drug supply managers that they were concerned about the impact of drug oversupply across the entire supply chain, including raw materials, manufacturing, storage, shipping, and packing materials. Helping study managers fine-tune supply can maximize trial resources and increase efficiencies."
Reference: Suvoda Introduces Advanced Drug Optimization for IRT to Improve Accuracy of Clinical Trial Drug Supply Management. PR Newswire. October 12, 2023. Accessed October 13, 2023. https://www.prnewswire.com/news-releases/suvoda-introduces-advanced-drug-optimization-for-irt-to-improve-accuracy-of-clinical-trial-drug-supply-management-301951747.html
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Managing Side Effects and Dosing in Off-Label GLP-1 Use with Help from Real-World Evidence
July 18th 2025Shipra Patel, global therapeutic area section head, endocrinology, global head, pediatrics, Parexel, explains how real-world data is helping researchers navigate gastrointestinal side effects, dose flexibility, and long-term tolerability in off-label GLP-1 use.
Anselamimab Misses Primary Endpoint in Phase III CARES Trials for AL Amyloidosis
July 17th 2025In the Phase III CARES trials, anselamimab did not meet the primary endpoint for advanced-stage AL amyloidosis, but a prespecified subgroup analysis revealed meaningful improvements in survival and cardiovascular outcomes.
